Login
Navigate Fool.com
Will INO beat
the market?

Inovio Biomedical Corp. (NYSEMKT: INO)

Community Rating: 2 Stars: Unattractive

12.98 -0.12 (-0.92%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.92
Previous Close $13.10
Daily Range $12.43 - $13.40
52-Week Range $4.88 - $15.80
Market Cap $780.8M
P/E Ratio -9.36
Dividend (Yield) $0.00 (0.0%)
Volume 3,596,946
Average Daily Volume 2,032,791
Current FY EPS -$0.71

How do you think INO
will perform against the market?

Top INO Bull/Bear Pitches

 

ColossalSlug (2.24)
Submitted March 13, 2014

Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the busin … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted August 16, 2013

Letting go of a green thumb on a tiny biopharma that's turned itself into a sudden multibagger is always a tough decision. I've dropped out so many times content with a couple of hundred points only t … More

3 Replies Reply Report this Post

News & Commentary

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit

The health care sector saw a flurry of major news yesterday. Here are three key stories that investors may have missed.

Why Inovio Pharmaceuticals Inc Stock Livened Up Today

A phase 2 trial success lifts hope around Wall Street for Inovio's HPV-fighting vaccine VGX-3100

Roundtable: 3 Stocks Janet Yellen Would Hate

The Fed thinks biotech stocks are overvalued. Here's where they're right.

Tuesday Sector Laggards: Biotechnology, Drugs

Why Merck Should Buy Inovio, Seattle Genetics, or MannKind

Merck could be gearing up for an acquisition spree. Could Inovio, Seattle Genetics, and MannKind be potential takeover targets?

5 of Last Week's Biggest Winners

These five stocks posted double-digit percentage gains.

Is Inovio Poised to Climb, or Will It Tumble?

VGX-3100 is a big opportunity for Inovio -- and a big risk.

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

3 Stocks Crushed by the Market This Week

Double-digit declines in just a few days. Here's three of this week's worst health-care stocks.

Are Investors Wrong About Inovio Pharmaceuticals?

Inovio Pharmaceuticals is on the cusp of a pivotal mid-stage data readout. Heading into this event, shorts have been jumping into the stock with both feet. Here's why.

See More INO News...

Sector

Healthcare

Industry

Drugs

Inovio Biomedical Corp. (INO) Description

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals. Website: http://www.inovio.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks